CA2316447A1 - Rantes mutants and therapeutic applications thereof - Google Patents

Rantes mutants and therapeutic applications thereof Download PDF

Info

Publication number
CA2316447A1
CA2316447A1 CA002316447A CA2316447A CA2316447A1 CA 2316447 A1 CA2316447 A1 CA 2316447A1 CA 002316447 A CA002316447 A CA 002316447A CA 2316447 A CA2316447 A CA 2316447A CA 2316447 A1 CA2316447 A1 CA 2316447A1
Authority
CA
Canada
Prior art keywords
rantes
therapeutic applications
rantes mutants
mutants
wild
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002316447A
Other languages
French (fr)
Other versions
CA2316447C (en
Inventor
Paolo Lusso
Simona Polo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fondazione Centro San Raffaele del Monte Tabor
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ITMI972865 external-priority patent/IT1297015B1/en
Priority claimed from IT98MI001866 external-priority patent/IT1302012B1/en
Application filed by Individual filed Critical Individual
Publication of CA2316447A1 publication Critical patent/CA2316447A1/en
Application granted granted Critical
Publication of CA2316447C publication Critical patent/CA2316447C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

RANTES mutants characterised by the substitution or addition of amino acids at the N-terminal of RANTES wild-type sequence and in the N-loop and/or 40's loop regions of RANTES wild-type sequence, and their use as anti-HIV, anti-allergic or anti-inflammatory agents.
CA002316447A 1997-12-23 1998-12-21 Rantes mutants and therapeutic applications thereof Expired - Fee Related CA2316447C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
ITMI97A002865 1997-12-23
ITMI972865 IT1297015B1 (en) 1997-12-23 1997-12-23 RANTES mutants, useful for inhibiting HIV
IT98MI001866 IT1302012B1 (en) 1998-08-07 1998-08-07 RANTES mutants, useful for inhibiting HIV
ITMI98A001866 1998-08-07
PCT/EP1998/008354 WO1999033989A2 (en) 1997-12-23 1998-12-21 Rantes mutants and therapeutic applications thereof

Publications (2)

Publication Number Publication Date
CA2316447A1 true CA2316447A1 (en) 1999-07-08
CA2316447C CA2316447C (en) 2009-07-28

Family

ID=26331556

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002316447A Expired - Fee Related CA2316447C (en) 1997-12-23 1998-12-21 Rantes mutants and therapeutic applications thereof

Country Status (10)

Country Link
US (2) US6608177B1 (en)
EP (2) EP1431391B1 (en)
JP (1) JP4323094B2 (en)
AT (2) ATE308617T1 (en)
AU (1) AU2415599A (en)
CA (1) CA2316447C (en)
DE (2) DE69832216T2 (en)
DK (2) DK1040191T3 (en)
ES (2) ES2247475T3 (en)
WO (1) WO1999033989A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6743594B1 (en) 1995-06-06 2004-06-01 Human Genome Sciences, Inc. Methods of screening using human G-protein chemokine receptor HDGNR10 (CCR5)
US6025154A (en) 1995-06-06 2000-02-15 Human Genome Sciences, Inc. Polynucleotides encoding human G-protein chemokine receptor HDGNR10
UA77950C2 (en) * 2000-10-04 2007-02-15 Applied Research Systems Use of mutants of cc chemokines for treatment of multiple sclerosis
IL162600A0 (en) 2001-12-17 2005-11-20 Applied Research Systems Cc-chemokine mutants as cc-chemokine antagonists
PT1494703E (en) * 2002-04-04 2006-05-31 Applied Research Systems MUTANT CHEMIOCINES WHICH HAVE AN IMPROVED ORAL BIOLOGICAL AVAILABILITY
US7981410B2 (en) * 2006-11-13 2011-07-19 Functional Genetics, Inc. Therapeutic targeting of escort proteins
MX2010001307A (en) 2007-08-02 2010-07-30 Novimmune Sa Anti-rantes antibodies and methods of use thereof.
CA3101052A1 (en) 2018-05-28 2019-12-05 ORION Biotechnology Switzerland Sarl Methods of inhibiting cerebral inflammation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9703889A (en) * 1994-12-08 1997-08-30 Glaxo Group Ltd Rantes peptide and fragments and compositions comprising it for treatment of inflammation.
FR2748938B1 (en) * 1996-05-22 1998-07-31 Pasteur Institut USE OF ANTAGONIST MOLECULES OF CHEMOKINES FOR THEIR ANTIVIRAL ACTIVITY IN PARTICULAR AGAINST HIV-TYPE RETROVIRUSES
AU4561497A (en) * 1996-09-25 1998-04-17 British Biotech Pharmaceuticals Limited Human rantes mutants incapable of aggregate formation

Also Published As

Publication number Publication date
DE69832197T2 (en) 2006-05-24
ATE308616T1 (en) 2005-11-15
US20030216549A1 (en) 2003-11-20
DK1040191T3 (en) 2005-12-19
EP1040191B1 (en) 2005-11-02
EP1431391B1 (en) 2005-11-02
WO1999033989A3 (en) 1999-08-26
JP2002507388A (en) 2002-03-12
ATE308617T1 (en) 2005-11-15
WO1999033989A2 (en) 1999-07-08
DE69832216D1 (en) 2005-12-08
DE69832197D1 (en) 2005-12-08
EP1431391A3 (en) 2004-10-06
JP4323094B2 (en) 2009-09-02
ES2247475T3 (en) 2006-03-01
US7164000B2 (en) 2007-01-16
DK1431391T3 (en) 2005-12-19
DE69832216T2 (en) 2006-05-24
EP1040191A2 (en) 2000-10-04
AU2415599A (en) 1999-07-19
EP1431391A2 (en) 2004-06-23
CA2316447C (en) 2009-07-28
ES2247738T3 (en) 2006-03-01
US6608177B1 (en) 2003-08-19

Similar Documents

Publication Publication Date Title
AU4403689A (en) Hiv proteins and peptides useful in the diagnosis, prophylaxis or therapy of aids
IL110284A0 (en) Viral vectors and their use in gene therapy
WO1998055508A3 (en) HUMAN PROTEINS HAVING TRANSMEMBRANE DOMAINS AND DNAs ENCODING THESE PROTEINS
WO1995007992A3 (en) Cloned glutamic acid decarboxylase
BG102362A (en) New derivatives of amino acids, their preparation and application
CA2120153A1 (en) Recombinant immunotoxins
CA2123315A1 (en) Therapeutic agents which are antagonists or partial agonists of human interleukin 4
AU1384995A (en) Human circulating cytokine cc-1
CA2316447A1 (en) Rantes mutants and therapeutic applications thereof
AU5591296A (en) N-((1,4-diazabicyclo(2.2.2)oct-2-yl)methyl)benzamide derivatives, their preparation and their application in therapeutics
AU4985596A (en) Novel aroylaniline derivatives, compositions and uses thereof in the treatment of viral infections
WO1998031712A3 (en) Chitosan-conjugates with acidic chelate-complex forming agents
CA2163805A1 (en) Novel activating factor of leukocytes
IT1244880B (en) FORMULATIONS OF LYOPHILIZED AMINO ACIDS CONTAINING GLUTAMINE, THEIR PREPARATION AND USE IN THE PARENTERAL FEEDING
CA2118498A1 (en) A novel anti-neoplastic cytokine
Dozeman The Life of Moses: The Yahwist as Historian in Exodus-Numbers
CA2247998A1 (en) Fragments of cr1 and their use
WO2000027881A3 (en) Human interleukin 10 mutant proteins
CA2088370A1 (en) New use of monoclonal antibody
IE873214L (en) Peptides
Hare The" Apotheosis of protestantism": the concept of work in Carlyle.
AU619080B2 (en) 2,4-dihalogeno-6-pyridylethanolphenylisopropylamines, processes for their preparation and their use for shifting the protein-fat ratio in favour of protein
AU1209797A (en) Novel antigenic proteins of mycoplasmata, genes thereof, and recombinant vector and use of the same
TH23850EX (en) bottle
TH13608EX (en) chair

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20131223